Clinical and Experimental Gastroenterology (Feb 2021)
Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis: An Updated Review of Current Preventive Strategies
Abstract
Harshil Bhatt1,2 1Goshen Hospital, Goshen, IN, USA; 2Indiana University School of Medicine, South Bend, IN, USACorrespondence: Harshil BhattGoshen Hospital, 200 High Park Ave, Goshen, IN 46526, USATel +1 574-364-2510Fax +1 844-850-7282Email [email protected]: Pancreatitis is a serious complication of endoscopic retrograde cholangiopancreatography, with incidence rates as high as 16% in some centers. Recent studies have also shown an upward trend in hospitalization due to endoscopic retrograde cholangiopancreatography-related pancreatitis. Early interventions taken before, during, and after the procedure can significantly reduce the risk of pancreatitis and decrease morbidity and mortality of the patients. To select appropriate patients for endoscopic retrograde cholangiopancreatography, in-depth knowledge of the patient-related and procedure-related risk factors is required. This updated clinical review outlines various pharmacological agents and surgical methods used for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis. Current evidence supports the use of rectal non-steroidal anti-inflammatory drugs and pancreatic stent placement as an effective preventive strategy. Further research is needed to compare these preventive modalities to improve patient outcomes after endoscopic retrograde cholangiopancreatography.Keywords: ERCP, post-ERCP pancreatitis, endoscopic retrograde cholangiopancreatography, rectal non-steroidal anti-inflammatory drugs, pancreatic stent
